Obesity & Diabetes Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity & Diabetes Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Diet & Nutrition
Nutrition technology company finds new soft chewable tablet reduces food intake by 20%
March 6th, 2006
PacificHealth Laboratories, Inc. (PHLI) announced that a double-blind, placebo-controlled study of appetite suppressant technology, a soft chewable tablet, demonstrated a 20% reduction in caloric intake in overweight individuals. Dr. Robert Portman, CEO of PHLI, said, "Results from this latest clinical study provide additional evidence on the effectiveness of our improved formulation. The study, which was funded by PHLI, was conducted with 20 overweight subjects with an average body mass index (BMI) of 28." Portman continued, "Subjects consuming the soft chewable tablet prior to an open-ended meal ate 20% less than those subjects who received the...
Source: Obesity & Diabetes Week (2006-03-06)
|
